Kambiz Yazdi
Stock Analyst at BTIG
(4.29)
# 1,313
Out of 4,382 analysts
57
Total ratings
51.1%
Success rate
22.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kambiz Yazdi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Maintained: Buy | $843 → $810 | $254.00 | +218.90% | 14 | Jun 2, 2026 | |
| RAPP Rapport Therapeutics | Maintained: Buy | $65 | $36.10 | +80.06% | 7 | Jun 1, 2026 | |
| ABSI Absci | Initiated Coverage: Buy | $9 | $6.40 | +40.63% | 1 | May 28, 2026 | |
| VTVT vTv Therapeutics | Maintained: Buy | $49 | $32.14 | +52.46% | 6 | May 13, 2026 | |
| SION Sionna Therapeutics | Rated: Buy | $58 | $35.37 | +63.98% | 7 | May 12, 2026 | |
| BME: PHM Pharma Mar, S.A. | Initiated Coverage: Buy | €121.00 | $96.15 | +25.85% | 1 | Apr 23, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | $23 | $10.61 | +116.78% | 2 | Apr 2, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintained: Buy | $31 | $21.23 | +46.02% | 6 | Jan 15, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $27 → $31 | $61.85 | n/a | 6 | May 28, 2025 | |
| AVTX Avalo Therapeutics | Initiated Coverage: Buy | $23 | $13.10 | n/a | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $11.78 | n/a | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.12 | n/a | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $14 | $0.3923 | n/a | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $7 | $0.0001 | n/a | 1 | May 31, 2023 |
Praxis Precision Medicines
Jun 2, 2026
Maintained: Buy
Price Target: $843 → $810
Current: $254.00
Upside: +218.90%
Rapport Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $65
Current: $36.10
Upside: +80.06%
Absci
May 28, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $6.40
Upside: +40.63%
vTv Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $49
Current: $32.14
Upside: +52.46%
Sionna Therapeutics
May 12, 2026
Rated: Buy
Price Target: $58
Current: $35.37
Upside: +63.98%
Pharma Mar, S.A.
Apr 23, 2026
Initiated Coverage: Buy
Price Target: €121.00
Current: $96.15
Upside: +25.85%
Zevra Therapeutics
Apr 2, 2026
Maintained: Buy
Price Target: $23
Current: $10.61
Upside: +116.78%
Arcutis Biotherapeutics
Jan 15, 2026
Maintained: Buy
Price Target: $31
Current: $21.23
Upside: +46.02%
Liquidia
May 28, 2025
Reiterated: Buy
Price Target: $27 → $31
Current: $61.85
Upside: n/a
Avalo Therapeutics
Mar 25, 2025
Initiated Coverage: Buy
Price Target: $23
Current: $13.10
Upside: n/a
Aug 28, 2024
Maintained: Buy
Price Target: $15
Current: $11.78
Upside: n/a
Apr 11, 2024
Initiated Coverage: Buy
Price Target: $5
Current: $1.12
Upside: n/a
Mar 7, 2024
Maintained: Buy
Price Target: $15 → $14
Current: $0.3923
Upside: n/a
May 31, 2023
Upgraded: Buy
Price Target: $7
Current: $0.0001
Upside: n/a